Most studies have reported group mean changes, while a few studies also analyzed intra-individual changes.
Though most studies have reported group differences in ASD reflecting a lack of differential response for ToM compared to baseline, one previous study also reported a relative deactivation for this contrast (in the RTPJ when making mentalistic judgements about the Queen's views; Lombardo et al., 2011).
The 15 most frequently reported (groups of) side effects by patients as well as the 15 most frequently reported (groups of) side effects by HCPs were included in the analysis.
Regarding the other adverse events, the most reported in the ZNS group were dizziness (5/33, 15.15% vs 2/18, 11.11% in the placebo group), somnolence (5/33, 15.15% vs 0/18, 0% in the placebo group), and headache (4/33, 12.12% vs 0/18, 0% in the placebo group).
In two of the three years (2008 and 2009) dissatisfaction with the coverage of the complementary insurance is one of the three most reported reasons for both groups.
Most reported patients were in age groups from 0 9 through 40 49 years (range 13.3%18.8%% per group; Table 2).
Individuals with multiple ethnicity codes were assigned their most commonly reported ethnicity group unless the most common ethnicity was 'not known' (NCIN, 2009).
NZ European was the most frequently reported ethnic group (53%) followed by Māori (19%), Asian (13%), Pacific (10%) and other ethnic groups (6%).
The most commonly reported surfactant group side effects included nasal burning and headache.
Overall, respondents most commonly reported a group practice setting (49%, 334/679), followed by solo practice (27%, 186/679), academic (14%, 96/679) and institutional (4%, 28/679).
